ArticleJournal of the Canadian Association of Gastroenterology2024

Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, Canada.

Thomas Tam Hoang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.